Efficacy Study of Outpatient Therapy for Lymphoma

Overview

This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.

Full Title of Study: “A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 2008

Detailed Description

Lymphoma has been increasing in incidence annually for the past several decades and the majority of patients relapse after first line therapy. A variety of 'salvage chemotherapy' treatments are available that are usually inpatient-based treatments associated with significant haematological toxicity. Furthermore, all patients are treated in the same manner despite the fact that some patients will do well irrespective of the type of salvage therapy whereas others will do badly no matter what is done. During 2001-2002 we undertook a pilot study in 40 such patients using an outpatient-based salvage therapy with 2 newer chemotherapy drugs, vinorelbine and gemcitabine. Over 75% of all treatments were successfully delivered on an outpatient basis with response rates similar to historical controls. We now propose to expand on these initial findings by modifying the outpatient approach for those patients with less favourable prognostic features, that is, patients will be stratified to differing therapies but with the majority still receiving the proven vinorelbine-gemcitabine combination.

Interventions

  • Drug: gemcitabine, vinorelbine, ifosfamide, filgastrim
    • Drug
  • Drug: gemcitabine, vinorelbine, filgastrim
    • Drug

Arms, Groups and Cohorts

  • Active Comparator: Commence VGF treatment
    • Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
  • Active Comparator: Commence F-GIV treatment
    • Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate the efficacy (overall response rate) of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim).
    • Time Frame: After two cycles and after four cycles

Secondary Measures

  • To evaluate safety,
    • Time Frame: Days 1 and 8 for every cycle, days 10,12,14, and 16 for first cycle.
  • relapse free survival,
    • Time Frame: After 2 cycles, 4 cyles and every 3 or 4 months for 12 months. Then every 6 months until disease progression
  • overall survival,
    • Time Frame: every 3 or 4 months for 12 months. Then every 6 months.
  • and planned dose-on-time.
    • Time Frame: After two cycles and after four cycles

Participating in This Clinical Trial

Inclusion Criteria

  • age > 18 years – relapsed or primary refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD) – ECOG 0 – 2 – written informed consent Exclusion criteria:

  • Intention to proceed with any form of transplant therapy following fewer than 2 cycles of protocol salvage therapy – bilirubin > 50μmol/litre unless secondary to lymphoma – creatinine > 2 x upper limit of normal unless secondary to lymphoma, absolute neutrophil count <0.5 x 109/litre and / or platelets < 50 x 109/litre unless secondary to lymphoma – relapse within 6 months of a prior transplant procedure (autologous or allogeneic) – known sensitivity to E coli derived preparations

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayside Health
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Andrew Spencer, Assoc. Prof, Study Chair,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.